Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- ?SARSCoV2 COVID19 2019nCoV SCoV2PLpro COVID19PLpro coronavirus PL pro IFN? IFN alpha IRF nsp 3 A 54 ORF 1ab
- Product Overview:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.{53462,53459,53461,55257,55258} The SARS-CoV-2 genome contains approximately 30 kilobases and 14 open reading frames (ORFs) that encode four structural proteins: spike, envelope, membrane, and nucleocapsid, as well as 16 non-structural proteins and 9 accessory factors.{57176} The SARS-CoV-2 papain-like protease (PLpro) is encoded within the non-structural protein 3 (nsp3) region of ORF1ab. It cleaves non-structural proteins 1-3, which, together with non-structural proteins 4-16, form the replicase complex. In addition, it reverses certain post-translational modifications, preferentially removing interferon-stimulated gene product 15 (ISG15), but also removing ubiquitin, from host proteins with both actions leading to suppression of the host innate immune response.{54466,54467} SARS-CoV-2 PLpro decreases IFN-?-induced ISGylation of IFN regulatory factor 3 (IRF3) in A549 cells and inhibits the type I IFN response.{54467} Inhibition of SARS-CoV-2 PLpro activity reduces SARS-CoV-2 replication and viral particle release from infected cells in vitro and increases the level of IRF3 ISGylation. Cayman’s SARS-CoV-2 Papain-like Protease protein can be used for enzyme activity assays. This protein consists of 324 amino acids and has a calculated molecular weight of 36.8 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.